Therapeutic Strategy Details
| Strategy ID: | S01 |
| Strategy: | Improve insulin resistance |
| Other Terms: | insulin sensitizer; insulin resistance; glucose tolerance |
| Related Targets: | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist |
| Related Drugs: | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide |
| Mechanism: | T2DM results from multiple organ abnormalities and various pathophysiological abnormalities. It has been linked to insulin resistance and obesity, indicating that T2DM and NAFLD have similar pathophysiological underpinnings. Therapeutic concepts such as thiazolidinediones (glitazones) for treating T2DM also show some efficacy in the treatment of NASH. |
| Reference (PMIDs): | 11567710; 27729660; 32044314 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D001 | Acarbose | Chemical drug | DB00284 | MGAM inhibitor;AMY2A inhibitor; AMY2B inhibitor; GAA inhibitor | Improve insulin resistance | Under clinical trials | Details |
| D011 | Anthocyanin | Chemical drug | -- | -- | Anti-inflammatory | Failed in clinical trials | Details |
| D012 | Apararenone | Chemical drug | DB15024 | Aldosterone receptor | Improve insulin resistance | Under clinical trials | Details |
| D029 | Berberine | Chemical drug | DB04115 | AMPK activator | Improve insulin resistance | Under clinical trials | Details |
| D032 | Betaine | Chemical drug | DB06756 | DNMTs stimulant | Improve insulin resistance | Under clinical trials | Details |
| D033 | Bezafibrate | Chemical drug | DB01393 | PPARA agonist; PPARD agonist; PPARG agonist; NR1I2 partial agonist | Improve insulin resistance; Anti-inflammatory | Under clinical trials | Details |
| D040 | BIO89-100 | Biological drug | -- | FGF21 analog | Improve insulin resistance; Enhance lipid metabolism | Under clinical trials | Details |
| D046 | Pegbelfermin | Biological drug | DB15365 | FGF21 analog | Improve insulin resistance; Enhance lipid metabolism; Anti-fibrosis | Under clinical trials | Details |
| D058 | Canagliflozin | Chemical drug | DB08907 | SGLT2 inhibitor | Improve insulin resistance | Under clinical trials | Details |
| D107 | Diacerein | Chemical drug | DB11994 | ALOX5 inhibitor | Antiarthritic drug; antiinflammatory agent | Under clinical trials | Details |
| Candidate ID | Source ID | Source Type | Compound Type | Candidate Name | Inclusion Criteria | |
|---|---|---|---|---|---|---|
| R0391 | DB01067 | approved; investigational | small molecule | Glipizide | Therapeutic strategy associated | Details |
| R0690 | DB05064 | investigational | small molecule | INCB13739 | Therapeutic strategy associated | Details |
| R0875 | DB05804 | investigational | small molecule | Prasterone sulfate | Therapeutic strategy associated | Details |
| R1042 | DB06536 | investigational | small molecule | Tesaglitazar | Target associated | Details |
| R1164 | DB08834 | experimental; investigational | small molecule | Tauroursodeoxycholic acid | Indication associated | Details |
| R1254 | DB09230 | investigational | small molecule | Azelnidipine | Therapeutic strategy associated | Details |
| R1410 | DB11827 | approved; investigational | small molecule | Ertugliflozin | Target associated | Details |
| R1485 | DB13174 | experimental | small molecule | Rhein | Therapeutic strategy associated | Details |
| R1486 | DB13178 | approved; investigational; withdrawn | small molecule | Inositol | Therapeutic strategy associated | Details |
| R1541 | DB14751 | approved | biotech | Mecasermin rinfabate | Indication associated | Details |
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00004 | 35258780 | Chin J Integr Med | Protective Roles of Shilajit in Modulating Resistin, Adiponectin, and Cytokines in Rats with Non-alcoholic Fatty Liver Disease. | Details |
| A00009 | 35256195 | Thromb Res | Impaired fibrinolysis without hypercoagulability characterises patients with non-alcoholic fatty liver disease. | Details |
| A00010 | 35255811 | BMC Gastroenterol | The effect of daily consumption of probiotic yogurt on liver enzymes, steatosis and fibrosis in patients with nonalcoholic fatty liver disease (NAFLD): study protocol for a randomized clinical trial. | Details |
| A00014 | 35254877 | Arch Physiol Biochem | Resveratrol attenuates against high-fat-diet-promoted non-alcoholic fatty liver disease in rats mainly by targeting the miR-34a/SIRT1 axis. | Details |
| A00023 | 35251371 | Dis Markers | Dose-Response Associations of Metabolic Score for Insulin Resistance Index with Nonalcoholic Fatty Liver Disease among a Nonobese Chinese Population: Retrospective Evidence from a Population-Based Cohort Study. | Details |
| A00029 | 35250856 | Front Endocrinol (Lausanne) | Not Enough Fat: Mouse Models of Inherited Lipodystrophy. | Details |
| A00031 | 35250588 | Front Pharmacol | Platelets in Non-alcoholic Fatty Liver Disease. | Details |
| A00034 | 35249505 | Curr Drug Saf | Pioglitazone, Bladder Cancer and the Presumption of Innocence. | Details |
| A00041 | 35247611 | Mol Metab | Serum Amyloid A1 Exacerbates Hepatic Steatosis via TLR4 Mediated NF-κB Signaling Pathway. | Details |
| A00054 | 35241921 | J Inflamm Res | Reduction of Hepatic Steatosis, Oxidative Stress, Inflammation, Ballooning and Insulin Resistance After Therapy with Safranal in NAFLD Animal Model: A New Approach. | Details |
| A00056 | 35240344 | Cell Mol Gastroenterol Hepatol | Activation of Liver mTORC1 Protects Against NASH via Dual Regulation of VLDL-TAG Secretion and De Novo Lipogenesis. | Details |
| A00057 | 35238939 | J Clin Endocrinol Metab | Long or Irregular Menstrual Cycles and Risk of Prevalent and Incident Nonalcoholic Fatty Liver Disease. | Details |
| A00059 | 35238641 | Proc Natl Acad Sci U S A | Disruption of the circadian clock component BMAL1 elicits an endocrine adaption impacting on insulin sensitivity and liver disease. | Details |
| A00085 | 35226250 | Cell Biol Toxicol | AS3MT facilitates NLRP3 inflammasome activation by m6A modification during arsenic-induced hepatic insulin resistance. | Details |
| A00089 | 35223701 | Front Pediatr | Association Between Non-invasive Diagnostic Methods of Liver Fibrosis and Type 2 Diabetes in Pediatric Patients With Non-alcoholic Fatty Liver Disease. | Details |
| A00091 | 35222903 | Ther Adv Chronic Dis | Nicotinamide supplementation in diabetic nonalcoholic fatty liver disease patients: randomized controlled trial. | Details |
| A00093 | 35222075 | Front Physiol | MicroRNA-122-5p Inhibition Improves Inflammation and Oxidative Stress Damage in Dietary-Induced Non-alcoholic Fatty Liver Disease Through Targeting FOXO3. | Details |
| A00103 | 35218234 | Hepatology | Dual roles of B lymphocytes in murine models of diet-induced non-alcoholic fatty liver disease. | Details |
| A00114 | 35216326 | Int J Mol Sci | New Insights in the Control of Fat Homeostasis: The Role of Neurotensin. | Details |
| A00115 | 35216174 | Int J Mol Sci | Whole Body Ip6k1 Deletion Protects Mice from Age-Induced Weight Gain, Insulin Resistance and Metabolic Dysfunction. | Details |